Marken's Approach to Improve Supply Chain Capabilities

Marken's Approach to Improve Supply Chain Capabilities

By Pharma Tech Outlook | Thursday, January 17, 2019

In the field of biomedical research, gene therapy and cell therapy have similar therapeutic goals. Recently, the cell and gene therapy increased the emphasis on the design and implementation of different supply chain models. It supported the movement of materials and drug product for providing better care to patients. These therapies have unpredictable sources of manufacturing. There are several cells and gene therapy providing an organization which transforms the system of medicine by organizing the use of genetic and cellular therapies to control and cure human disease.

Marken, a company based in London, provides supply-chain services to the life sciences industry and stores and distributes clinical trial materials. A subsidiary of United Parcel Service Inc., Marken, remains to be the chosen provider for global cell and gene trials around the world. It understands the importance of each shipment for patients and their families.

Wes Wheeler, Chief Executive Officer for Marken, says, “The collaboration between Marken and TrakCel is a natural next step in our strategy to expand Marken's service offerings into the cell and gene clinical supply chain market. We also ensure 100% of all cell and gene shipments travel with our GPS tracking technology and are monitored by our 24/7 Global Control Center.”

Technology plays a key role in the supply chain. TrakCel has chosen it to deepen its capabilities to provide its service. TrakCel has developed leading integrated technology to organize the supply chain for therapies efficiently and easily. The software tracks the registration of patients and donors, the collection of materials, production, shipping data, and details of the final infusion of patients. The interface between TrakCel’s and Marken’s operating systems allows users to automatically schedule or modify material collections according to the production capacity and treatment schedules of each health care provider. Clinicians can then see the progress of therapies at each stage of the supply chain.

Weekly Brief

New Editions